Kornimate/medical-research-clean huggingface dataset:
treating self-criticism in adolescents: a study with single-case experimental design

Conditions: Adolescent - Emotional Problem; Adolescent Problem Behavior; Nonsuicidal Self Injury; Depressive Symptoms; Anxiety; Self-Criticism

Summary: in this pilot study, the effect of a group intervention targeting self-criticism in adolescents in a clinical child- and adolescent psychiatric outpatient setting will be examined using a single-case experimental design (ab). participants will be randomized to multiple baseline with weekly measures. our primary outcomes, measured weekly, are self-criticism, nonsuicidal self-injury and symptoms of depression and anxiety, as well as an individually chosen behavior driven by self-criticism. secondary outcomes are self-compassion, psychological flexibility, quality of life and functioning. in addition to the weekly administered questionnaires, before and after measures, and 3- and 6-month follow-up will be collected. after the treatment, participants will also be interviewed about their experiences of targeting self-criticism.


Eligibility criteria:
inclusion criteria: * patient at the child- and adolescent psychiatric clinic in linköping, sweden. * 15 to 18 years * an adequate understanding of the swedish language * cognitively capable of giving informed consent * scoring 26 or above on subscale "inadequate self" and 8.5 or above on subscale "hated self" on questionnaire forms of self-criticism and self-reassuring scale (fscrs) * the treatment is transdiagnostic so all diagnoses are included (see exclusion criteria for exceptions). exclusion criteria: * severe anorexia, bmi ≤ 16 * ongoing substance abuse * diagnosed intellectual disability * needing interpreter for translation of swedish language * participants who cannot give informed consent

Keywords: self-criticism adolescents group intervention single-case experimental design
a phase 3 extension study to investigate the long-term safety, tolerability and efficacy of pa21, a phosphate binder in dialysis patients

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis

Summary: this is a phase 3, randomised, active controlled, multicentre extension study to investigate the long-term safety and efficacy of pa21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. this is an extension study to pa-cl-05a (nct01324128), subjects have already been enrolled and have been treated with study medication for at least 24 weeks.


Eligibility criteria:
inclusion criteria: * subjects who have completed treatment in protocol pa-cl-05a * written informed consent exclusion criteria: * hyper/hypo calcemia; hyper intact parathyroid hormone (ipth) * other significant medical conditions * pregnancy

Keywords: pa21 phosphate binder
comparative effects of hang clean and half squat training program among basketball players

Conditions: Weight-Bearing Strengthening Program; Muscle Strength; Basketball

Summary: the goal of this randomized controlled trial is to compare the effects of hang clean and half squat training programs on vertical jump performance and strength in male basketball players aged 18-35 years. the main questions it aims to answer are: does a hang clean training program improve vertical jump performance in basketball players? does a half squat training program improve vertical jump performance in basketball players? researchers will compare the hang clean training group to the half squat training group to see if there is a significant difference in the improvement of vertical jump performance and strength. participants who meet the inclusion criteria will be enrolled and allocated in group a \& b through sealed envelop method by non-probability convenient random sampling technique. subjects in group a will receive hang clean training. group b will receive half squat training, attend pre- and post-testing assessments of vertical jump performance and strength

explosive strength is a crucial factor in basketball performance, and various training programs have been developed to improve it. the goal of this randomized controlled trial is to determine the effectiveness of a 12-weeks hang clean training program versus a 12-week half squat training program in improving vertical jump performance and strength in male basketball players aged 18-35 years. the main questions it aims to answer are: is hang clean training effective in improving vertical jump performance and strength in basketball players? is half squat training effective in improving vertical jump performance and strength in basketball players? researchers will compare the hang clean training group to the half squat training group to see if there is a significant difference in the improvement of vertical jump performance and strength. ethical approval is taken from ethical committee of riphah international university, lahore. participants who meet the inclusion criteria will be enrolled and allocated in group a \& b through sealed envelop method by non-probability convenient random sampling technique. study will be carried in basketball courts at lahore. participants will be randomly assigned to either the hcl or hsq training group. group a will receive hang clean training. group b will receive half squat training.

Eligibility criteria:
inclusion criteria: * male basketball player * having experience with weight-lifting movements, squats, and deadlifts * no history of anterior cruciate ligament injuries * no present complaint of injury. * 3 years of professional experience * current competitive level exclusion criteria: * medical condition * previous history of lbp * orthopedic or health related conditions * female * inadequate training experience * exclude performance-enhancing substance

Keywords: weight lifting resistance training basketball players
von willebrand factor levels in patients with liver cirrhosis and portal hypertension

Conditions: Liver Cirrhosis; Portal Hypertension

Summary: verify von willebrand factor role in patients with liver cirrhosis and portal hypertension

patients with cirrhosis have an endotoxemic medium due to intestinal flora changes, decreased hepatic clearance of endotoxins and transition of bacteria to mesenteric lymph nodes from intestinal barrier .serum von willebrand factor (vwf) increases in a linear ratio with the intensity of endotoxemia. portal hypertension (ph) is a hallmark of advanced chronic liver disease (acld) that significantly influences the onset of liver-related complications and mortality. it can be quantified using the minimally invasive measurement of the hepatic venous pressure gradient (hvpg). experimental research has demonstrated that ongoing dysfunction of liver sinusoidal endothelial cells (lsec) triggers the activation of hepatic stellate cells (hsc) and leads to intrahepatic vasoconstriction, thereby contributing to ph. von willebrand factor (vwf) is released by activated endothelial cells and plays a crucial role in hemostasis by facilitating the adhesion of platelets to subendothelial collagen and other platelet-adhesive proteins exposed during vascular injury. early studies revealed that vwf levels are elevated in patients with acld, linking this finding to endothelial dysfunction likely caused by endotoxemia , resulting from pathological bacterial translocation. notably, vwf antigen (vwf-ag) has shown diagnostic potential for clinically significant ph (csph; defined by an hvpg ≥ 10 mmhg) and prognostic value for disease progression, even after the underlying cause has been treated. elevated vwf levels may help balance the fragile hemostatic system in patients with acld by compensating for platelet deficiencies in number and possibly function. vwf is more than just a hemostatic protein; it serves as a marker of endothelial dysfunction in patients with cirrhosis.vwf levels can independently predict decompensation and mortality in cirrhosis patients, regardless of the stage of liver disease and severity of portal hypertension. the vwf-to-thrombocyte ratio (vitro) score enhances the diagnostic capability of vwf alone in noninvasively detecting csph.in addition to predicting the risk of hepatocellular carcinoma (hcc) in cirrhosis patients, vwf levels also forecast the risk of complications following hcc resection and response to systemic therapies.

Eligibility criteria:
inclusion criteria: * adult patient \>18 years * both sex male and female * all stages of liver cirrhosis (compensated and decompensated) exclusion criteria: * acute liver disease * any hereditary or acquired diseases that affect vwf level. * sepsis and infections (including spontaneous bacterial peritonitis), patients with any infectious symptoms at the time of study (increasing vwf ag levels). * active extrahepatic malignancies. * previous liver transplantation. * any medication affect vwf level.

Keywords: von willebrand factor liver cirrhosis portal hypertension
a frontline therapy trial in participants with advanced classical hodgkin lymphoma

Conditions: Hodgkin Lymphoma

Summary: this open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mpfs) obtained with brentuximab vedotin (adcetris®) plus avd (doxorubicin \[adriamycin\], vinblastine, and dacarbazine; abbreviated a+avd) versus that obtained with abvd (doxorubicin \[adriamycin\],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical hodgkin lymphoma(hl)


Eligibility criteria:
inclusion criteria: 1. treatment-naïve participants with ann arbor stage iii or iv hl. 2. histologically confirmed classical hodgkin lymphoma (hl) according to the current world health organization (who) classification. 3. eastern cooperative oncology group (ecog) performance status less than or equal to (\<=) 2. 4. bidimensional measurable disease as documented by radiographic technique per the international working group revised criteria for response assessment for malignant lymphoma. exclusion criteria: 1. nodular lymphocyte predominant hodgkin lymphoma. 2. cerebral/meningeal disease, including signs and symptoms of progressive multifocalleukoencephalopathy (pml). 3. sensory or motor peripheral neuropathy. 4. prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy within 12 weeks of first study drug dose. 5. known human immunodeficiency virus (hiv) positive. 6. known hepatitis b surface antigen-positive, or known or suspected active hepatitis c infection. please note that there are additional exclusion criteria. the study center will determine if you meet all of the criteria.

Keywords: hodgkin lymphoma hodgkins lymphoma antibody, monoclonal antibody-drug conjugate antigens, cd-30 immunotherapy lymphoma lymphoma, classical echelon-1
trial of a nationwide cognitive-affective remediation training intervention in depression

Conditions: Cognitive-affective Exercises; Engaging Exercises

Summary: the objective is to examine the efficacy of computerized interventions for increasing well-being and cognitive functioning. the study will seek to validate emerging online delivery methods of psychiatric assessment and treatment. this will allow us to test the efficacy of this intervention in a larger and more geographically broad sample than is possible through traditional recruitment and treatment, and to do so in a highly cost-effective manner.


Eligibility criteria:
inclusion criteria: * computer and broadband internet access * 18 years of age * elevated anxiety and depression * native english speaker exclusion criteria:
glucose homeostasis in pseudohypoparathyroidism

Conditions: Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism; Pseudohypoparathyroidism Type Ia; Albright Hereditary Osteodystrophy

Summary: it is increasingly recognized that pseudohypoparathyroidism type 1a (php1a) is associated with an increased risk of type 2 diabetes but the mechanism is unknown. in this pilot study we will assess β-cell function in patients with php1a and pseudopseudohypoparathyroidism pphp.

pseudohypoparathyroidism type 1a (php1a) is a rare, genetic disorder caused by impaired stimulatory g-protein signaling due to heterozygous mutations in the gene, gnas. the most severe form of the disease, php1a occurs when a gnas mutation is inherited on the preferentially expressed maternal allele. a less severe form of the disease, pseudopseudohypoparathyroidism (pphp), occurs when a gnas mutation is inherited on the paternal allele. clinically, php1a is characterized by multi-hormone resistance, cognitive impairment and early-onset obesity while pphp has a mild phenotype without multi-hormone resistance. it is increasingly recognized that php1a is associated with an increased risk of type 2 diabetes but the mechanism is unknown. glucose homeostasis and diabetes risk has not been studied in pphp. as part of the parent k23 award, we investigated glucose tolerance in children with php1a. in contrast to the adult literature, we found that children with php1a had greater insulin sensitivity than matched controls. when challenged with an oral glucose load, however, children with php1a had persistent hyperglycemia and 25% met criteria for impaired glucose tolerance. the goal of this proposal is to quantify β-cell function in php1a. it is plausible that these individuals have a) impaired β-cell function, b) differences in insulin sensitivity, and c) impaired incretin function. thus, in this pilot study we will definitively assess one of these, β-cell function, using the frequently sampled intravenous glucose tolerance test in patients with php1a and pphp (aim 1). we will also assess oral glucose tolerance over time by bringing back children and young adults with php1a from our original cohort for repeat glucose tolerance testing (aim 2). the ultimate goal is to rigorously define glucose homeostasis defects in php1a in order to design and conduct an intervention study for glucose intolerance and type 2 diabetes in php1a.

Eligibility criteria:
inclusion criteria: 1. diagnosis of php1a/pphp 2. age between 6 and 50 years old controls will be matched based on: 1. gender 2. race 3. age (±2 years if \<25 years old or ±5 years if ≥25 years old) 4. bmi (±2 kg/m2) 5. diabetes status exclusion criteria: 1. treatment with appetite-altering drug or initiation of a new weight loss program in the past 3 months 2. type 1 diabetes 3. type 2 diabetes treated with insulin or glp-1 receptor agonists or a1c \>9%at their most recent clinic visit 4. pregnant or lactating women
role of mrs in brain lesions

Conditions: Brain Lesion (General); Mrs

Summary: aim of the study is evaluation of accuracy of magnetic resonance spectroscopy in differentiation between neoplastic and non neoplastic lesions and determination the type of neoplasm

the annual global age-standardized incidence of primary malignant brain tumors is \~3.7 per 100,000 for males and 2.6 per 100,000 for females . rates appear to be higher more in developed countries (males, 5.8 and females, 4.1 per 100,000) than in less developed countries (males 3.0 and females 2.1 per 100,000). more than half of all brain tumors are intraparenchymal . diagnosis of brain lesions and other focal intracranial lesions based on imaging methods alone is still facing a challenging problem. accurate diagnosis is fundamentally vital for clinical management in patients with brain tumors. ct and standard mri are the first line imaging modalities in evaluation of brain lesions; however, it does not always provide more precise details and characterization of the lesions whether it is benign or malignant. conventional imaging techniques do not provide exact information about vascularity, cellularity and metabolism of the mass lesion . magnetic resonance spectroscopy (mr spectroscopy) is one of the tools used to determine themolecular structures of compounds or to detect the compound presence. mr spectroscopy provides metabolic information from living tissues. the major brain metabolites detected are choline, creatine, n-acetyl aspartate (naa), lactate, myoinositol, glutamine, glutamate, lipids and the amino acids leucine and alanine. brain lesions show abnormal values of these metabolites as compared to normal tissue.our study aims to determine the accuracy of mrs in differentiation between neoplastic and non neoplastic lesions and determination the type of neoplasm, discriminating neoplastic from non-neoplastic brain lesions is extremely necessary since a misdiagnosis can lead to a severe effect on neurosurgery and exposure to toxic chemotherapy or radiotherapy, which may cause damage to brain tissues.

Eligibility criteria:
inclusion criteria: * patients with solitary intraaxial brain lesions * patients with de novo lesions * patient age : any age exclusion criteria: * patients with multiple intra-axial brain lesions * patients with extra-axial brain lesions * patients with recurrent lesions * patients receiving chemotherapy or radiotherapy * patients unfit for surgery
phase iii randomized study of sodium dichloroacetate in children with congenital lactic acidosis

Conditions: Lactic Acidosis

Summary: objectives: i. compare the safety of sodium dichloroacetate (dca) vs placebo in children with congenital lactic acidosis. ii. determine the quality of life of these patients. iii. determine the pharmacokinetics and metabolic fate of dca over the course of drug administration in these patients.

protocol outline: this is a randomized, double blind, crossover study. patients are stratified according to age (3 months to 2 years vs over 2 to 18 years). all patients receive at least 12 months of sodium dichloroacetate (dca) during a 2 year period of double blind, crossover evaluation of dca and placebo by mouth. quality of life is assessed before treatment and periodically during treatment. completion date provided represents the completion date of the grant per oopd records

Eligibility criteria:
protocol entry criteria: --disease characteristics-- diagnosis of congenital lactic acidosis (cla) meeting the following criteria: three basal venous lactates at least 2.5 mm, arterial lactates at least 2.0 mm, or csf lactates at least 2.5 mm or any combination of these, obtained over at least 1 month and within 6 months or increase in blood lactate at least 1.0 mm over basal following a carbohydrate meal challenge and enzymatic or molecular genetic proof of a defect of pyruvate dehydrogenase complex, one or more respiratory chain enzymes, or a krebs cycle enzyme or over production of c14-lactate from c14-glucose by cultured skin fibroblasts and ability to withstand an 8 hour (if 2 years and under) or 12 hour (if over 2 years) fast without developing hypoglycemia (blood glucose less than 50 mg/dl) no secondary lactic acidosis due to impaired oxygenation or circulation no hyperlactatemia associated with proven biotinidase deficiency (biotin responsive cla) or with enzyme deficiencies of gluconeogenesis no primary, defined organic acidurias other than lactic acidosis, for which effective therapy is available (e.g., propionic aciduria) no primary disorders of amino acid metabolism or fatty acid oxidation no malabsorption syndromes associated with d-lactic acidosis --prior/concurrent therapy-- no chronic dialysis --patient characteristics-- hepatic: no primary hepatic disease unrelated to cla renal: creatinine less than 1.2 mg/dl or creatinine clearance at least 60 ml/min other: no concurrent infection or fever

Keywords: disease-related problem/condition inborn errors of metabolism lactic acidosis quality of life rare disease
measurement of soluble factors and particulate matter in induced sputum and ebc in inflammatory diseases of the lung

Conditions: Asthma; Chronic Obstructive Pulmonary Disease; Interstitial Lung Diseases; Occupational Lung Diseases

Summary: in the present study inflammatory mediators will be isolated in induced sputum and exhaled breath condensate and will be correlated with particulate matter measured in these samples.particulate matter will be assessed by partcle size distribution method and shape analysis. the aim of the study is to perform biological monitoring in environmental and occupational diseases in a non invassive fashion.


Eligibility criteria:
inclusion criteria: * ages 7-80 exclusion criteria: * fev1 \< 75% predicted po2 \< 75

Keywords: primary disease or condition being studied: asthma -copd-interstitial lung diseases-occupational lung diseases
can we train patients with chronic stroke out of abnormal hand synergy?

Conditions: Cerebral Stroke

Summary: this study plans to determine whether training can change abnormal flexion synergy in chronic stroke patients.

the aim of the current study is to investigate whether motor training in chronic stroke patients can change their abnormal flexion synergy. the investigators will study chronic stroke patients , who are defined as patients that sustained a stroke at least 6 months prior to our testing date. three functional aspects of each finger will be tested: maximal voluntary contraction (mvc), finger dexterity, and hand posture. prior to intervention, participants will have a baseline assessment including clinical tests, mvc, the individuation task, and the configuration task. following the baseline assessment patients will receive intervention, training on the configuration task for 5 consecutive days. on the sixth day and as a one week follow-up after, subjects will have a post-intervention assessment containing the same tests performed in baseline. this design will allow us to determine speed and accuracy during the configuration task, the individuation index, and possible changes in abnormal flexion synergy. we initially registered the study as two arms (anodal tdcs and sham tdcs groups) but decided to make it one arm due to the number of participants we were able to recruit.

Eligibility criteria:
inclusion criteria: * age 21 and older * ischemic stroke greater than six months ago, confirmed by ct or mri * residuals unilateral upper extremity weakness * ability to give informed consent and understand the tasks involved. * appearance of flexion synergy in hand. * ability to extent finger at least for 5 degrees. exclusion criteria: * cognitive impairment, with score on montreal cognitive assessment (moca) ≤ 20 * history of physical or neurological condition that interferes with study procedures or assessment of motor function (e.g. severe arthritis, severe neuropathy, parkinson's disease) * contraindication to tdcs (deep brain stimulators or other metal in the head, skull defect, pacemaker) * inability to sit in a chair and perform upper limb exercises for one hour at a time * participation in another upper extremity rehabilitative therapy study or tdcs study during the study period * terminal illness * social and/or personal circumstances that interfere with ability to return for therapy sessions and follow up assessments * pregnancy * severe neglect

Keywords: motor recovery motor learning ischemic stroke